193 related articles for article (PubMed ID: 31697049)
21. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
[TBL] [Abstract][Full Text] [Related]
22. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
[TBL] [Abstract][Full Text] [Related]
23. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
[TBL] [Abstract][Full Text] [Related]
24. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers.
Soergel DG; Subach RA; Sadler B; Connell J; Marion AS; Cowan CL; Violin JD; Lark MW
J Clin Pharmacol; 2014 Mar; 54(3):351-7. PubMed ID: 24122908
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
[TBL] [Abstract][Full Text] [Related]
26. A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain.
Viscusi ER
Expert Rev Neurother; 2022 Jun; 22(6):419-426. PubMed ID: 35502668
[TBL] [Abstract][Full Text] [Related]
27. Oliceridine for the Management of Acute Postoperative Pain.
Liu Y; Hu Q; Yang J
Ann Pharmacother; 2021 Oct; 55(10):1283-1289. PubMed ID: 33423508
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
31. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
32. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
33. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
35. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice.
Liang DY; Li WW; Nwaneshiudu C; Irvine KA; Clark JD
Anesth Analg; 2019 Nov; 129(5):1414-1421. PubMed ID: 30044299
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Gepotidacin in Renal Impairment.
Hossain M; Tiffany C; Raychaudhuri A; Nguyen D; Tai G; Alcorn H; Preston RA; Marbury T; Dumont E
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):560-572. PubMed ID: 32429000
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment.
Hossain M; Tiffany C; Tao Y; Barth A; Marbury TC; Preston RA; Dumont E
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):588-597. PubMed ID: 33450142
[TBL] [Abstract][Full Text] [Related]
40. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
Singla N; Minkowitz HS; Soergel DG; Burt DA; Subach RA; Salamea MY; Fossler MJ; Skobieranda F
J Pain Res; 2017; 10():2413-2424. PubMed ID: 29062240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
